RxDoctor Payments Data

Holger Salazar, MD

Cardiovascular Disease · Memphis, TNNPI 1578679395

Payments from drug & device makers

$1,090in general payments, 2019–2025

Across 67 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$443
  • Actelion Pharmaceuticals US, Inc.$330
  • Amgen$77
  • Baxter Healthcare$55
  • Pfizer$55
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$47
  • plus $83 from 6 others

What the payments were for

  • Food & beverage$1,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,090 in reported general payments places this provider in the 35th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$374,504
Medicare patients
1,584
Services billed
9,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban410$457,371
JardianceEmpagliflozin218$220,656
CamzyosMavacamten25$204,639
FarxigaDapagliflozin Propanediol173$145,880
EntrestoSacubitril/Valsartan123$131,572
Repatha SureclickEvolocumab127$110,399
XareltoRivaroxaban79$85,895
KerendiaFinerenone56$56,776
OzempicSemaglutide45$50,473
MultaqDronedarone Hcl32$40,795
TrulicityDulaglutide33$39,450
RybelsusSemaglutide14$37,767
VascepaIcosapent Ethyl60$28,358
JanumetSitagliptin Phos/Metformin Hcl28$24,745
MounjaroTirzepatide15$18,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$457,371410 claims
AstraZenecaFarxiga, Brilinta$14$156,112185 claims
NovartisEntresto$443$131,572123 claims
Sanofi-aventis U.S. LLCMultaq$15$40,79532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →